Current Opinion in Oncology 

About: Current Opinion in Oncology is an academic journal published by Lippincott Williams & Wilkins. The journal publishes majorly in the area(s): Cancer & Medicine. It has an ISSN identifier of 1040-8746. Over the lifetime, 2738 publications have been published receiving 84584 citations.

Chronic myeloid leukemia.

Abstract: Chronic myeloid leukemia is an enigma in origin and a source of frustration in treatment because until recently no real progress had been made in altering its natural history. Nevertheless, recent advances in cell biology and molecular genetics, and a plethora of morphologic, biochemical, and cytogenetic data of potential clinical relevance have yielded new data regarding this disease. The use of marrow transplantation and recombinant interferon have been of significant clinical importance, although their roles in the overall treatment of the disease remain to be determined.

TGF-β signaling and epithelial-mesenchymal transition in cancer progression.

Abstract: Purpose of reviewTGF-β acts as a potent driver of cancer progression through the induction of epithelial–mesenchymal transition (EMT), in which epithelial cells acquire mesenchymal phenotype, leading to enhanced motility and invasion. Recent reports highlight the fundamental roles of TGF-β-induced E

Aneuploidy and cancer.

Abstract: Numeric aberrations in chromosomes, referred to as aneuploidy, is commonly observed in human cancer Whether aneuploidy is a cause or consequence of cancer has long been debated Three lines of evidence now make a compelling case for aneuploidy being a discrete chromosome mutation event that contrib

Histone deacetylase inhibitors as new cancer drugs.

Abstract: Histone deacetylase inhibitors are potent inducers of growth arrest, differentiation, or apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals. Histone deacetylases and the family of histone acetyl transferases are involved in determining the acetylation of histones, which play a role in regulation of gene expression. Radiograph crystallographic studies reveal that the histone deacetylase inhibitors, suberoylanilide hydroxamic acid and trichostatin A, fit into the catalytic site of histone deacetylase, which has a tubular structure with a zinc atom at its base. The hydroxamic acid moiety of the inhibitor binds to the zinc. Histone deacetylase inhibitors cause acetylated histones to accumulate in both tumor and peripheral circulating mononuclear cells. Accumulation of acetylated histones has been used as a marker of the biologic activity of the agents. Hydroxamic acid-based histone deacetylase inhibitors limit tumor cell growth in animals with little or no toxicity. These compounds act selectively on genes, altering the transcription of only approximately 2% of expressed genes in cultured tumor cells. A number of proteins other than histones are substrates for histone deacetylases. The role that these other targets play in histone deacetylase inducement of cell growth arrest, differentiation, or apoptotic cell death is not known. This review summarizes the characteristics of a variety of inhibitors of histone deacetylases and their effects on transformed cells in culture and tumor growth in animal models. Several structurally different histone deacetylase inhibitors are in phase I or II clinical trials in patients with cancers.

Oncogenic PI3K and its role in cancer.

Abstract: Purpose of reviewThe purpose of this review is to examine the contribution of the PI3K signaling pathway to the development of human tumors and to propose further studies to elucidate how to develop therapeutics for patients with mutations in this pathway.Recent findingsMore than 30% of various soli